Eduardo Bravo

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.